Dariush Mozaffarian,Haiming Cao,Gokhan S. Hotamisligil
申请号：
US15248310
公开号：
US20160361284A1
申请日:
2016.08.26
申请国别(地区):
US
年份:
2016
代理人:
摘要：
The present invention provides for a novel lipokine, trans-C16:1n7-palmitoleate, which also serves as a biomarker for metabolic status. More specifically, low concentrations of trans-C16:1n7-palmitoleate the serum indicates a risk of metabolic disease. Additionally, administering trans C16:1n7-palmitoleate to a subject (via pharmaceutical, nutraceutical, or other means), positively impacts glucose metabolism.
